Takeda Pharmaceutical Company Ltd

DelveInsight's report on Thrombocytopenia Market (2034) covers epidemiology, market trends in the US, EU4, UK, and Japan, highlighting the US as the largest market. Key companies include Sanofi, Principia Biopharma, Baxalta, Takeda, and others. Promising therapies such as VLX-1005, Herombopag, Avatrombopag Oral Tablet, Rilzabrutinib, and Nipocalimab are noted. Clinical trials by Qidong Gaitianli Medicines, Karyopharm Therapeutics, Janssen Research & Development, and Amgen are scheduled for June 2024. Marketed drugs like ADZYNMA (Takeda) and TAVALISSE (Rigel Pharmaceuticals/Kissei Pharmaceutical) are discussed. Emerging drugs like Rilzabrutinib (Sanofi/Principia Biopharma) are in Phase III for ITP treatment.

Yorvipath, the first hormone treatment for hypoparathyroidism, received FDA approval in August. The drug, developed by Ascendis Pharma, replaces missing PTH to restore calcium levels. Patient testimonials highlight significant improvements in quality of life. Additionally, MBX Biosciences and Septerna Therapeutics have made strides with their respective treatments, MBX 2109 and SEP-786, aiming to address the condition's challenges. AstraZeneca's acquisition of Amolyt Pharma for $800 million underscores the growing interest in hypoparathyroidism treatments.

Halozyme proposes to acquire Evotec for €11.00 per share, creating a leading global pharma services company with capabilities in drug discovery, biologic manufacturing, and drug delivery technologies, diversifying and scaling Halozyme's revenue and EBITDA into the next decade. The all-cash transaction would be funded by cash on hand and new debt, with expected net leverage less than 2x two years post-close.

Nanoform Q3 2024 report highlights record new non-GMP projects, revenue growth, and progress in GMP activities and product kernels. Key financials show revenue growth and increased gross profit, with ongoing manufacturing for pivotal studies and registration batches in Project Nanoenzalutamide. Dealmaking progress includes term sheets and LOIs, with expectations for license/commercial supply agreements. CEO's review emphasizes growth acceleration and strategic milestones achieved.

Ascentage Pharma's NDA for lisaftoclax, a Bcl-2 inhibitor for r/r CLL/SLL, was accepted by China's NMPA with Priority Review, potentially making it the first domestically developed Bcl-2 inhibitor in China and the second globally. This follows a Phase II study showing efficacy and safety in Chinese patients with r/r CLL/SLL, addressing a significant unmet need in China where CLL/SLL incidence is rising.

The 1034th NESACS Meeting and 2024 Medicinal Chemistry Symposium featured presentations on innovative treatments, including molecular glue degraders for sickle cell disease, SARS-CoV-2 inhibitors, WRN covalent inhibitors, and a CNS-penetrant RIPK1 inhibitor for neurodegeneration. Organized by a committee, it included a dinner and required registration.

IgA nephropathy affects 25-50 per million annually, with 20–40% progressing to end-stage kidney disease. Diagnosed cases in the US are expected to reach 135,000 by 2030. Treatments include ACE inhibitors, ARBs, corticosteroids, and immunosuppressants. FDA-approved treatments are TARPEYO, FILSPARI, and FABHALTA. The IgA nephropathy market is projected to reach ~USD 4.1 billion by 2034, driven by novel therapies like Novartis’ Atrasentan, Otsuka/Visterra’s Sibeprenlimab, Vertex/Alpine’s Povetacicept, and others.

Research on sleep apnea includes CPAP machines, mouth guards, and throat exercises. Lilly's tirzepatide showed significant AHI reduction in phase 3 trials. Epilepsy drug sulthiame also showed promise in sleep apnea trials. Apnimed's AD109 targets hypoglossal motor neurons, improving airway signals. Gut microbiome changes linked to sleep apnea severity suggest patient-specific therapies.

Yoshiaki Tsukamoto discusses Japan's Bio-Economy Strategy at BioJapan 2024, emphasizing open innovation, international collaboration, and advancements in regenerative medicine, cell therapy, precision medicine, and digital health. He highlights the importance of partnerships with Taiwan, the U.S., and Europe for global biotech progress.